• HemoSense (San Jose, California) said that it has signed an agreement with Laboratory Corporation of America (LabCorp; Burlington, North Carolina) to supply the HemoSense portable INRatio PT/INR monitoring system to identified LabCorp laboratories. The INRatio system will be made available to selected LabCorp patient service centers and affiliated physician offices nationwide. HemoSense’s INRatio system consists of a portable meter and disposable test strips that provide quick measurement of blood-clotting time, known as a PT/INR value. This test helps patients reduce the risk of strokes through frequent monitoring of anticoagulation therapy. HemoSense’s INRatio system is designed to reduce the time required to manage warfarin and allows patients to do self-management of warfarin dosage. The INRatio system is based on an electrochemical technology that generates rapid PT/INR results simultaneously with two levels of quality control from a single drop of blood.

Invitrogen (Carlsbad, California) and Cytori Therapeutics (San Diego) entered into a global strategic supply and commercialization agreement to offer adipose-derived stem cell-based research products to life science researchers. Invitrogen will offer Cytori’s stem cell products to broaden the understanding of adult stem cells and to discover and accelerate development of preclinical applications for adipose derived stem cells. Invitrogen provides technologies for disease research, drug discovery, and commercial bioproduction. Cytori is developing stem and regenerative cell therapies for cardiovascular disease, reconstructive surgery and many other serious chronic, and life threatening conditions.

• Osteotech (Eatontown, New Jersey) reported that it has expanded its tissue supply relationship with Community Tissue Services (CTS; Dayton, Ohio). Osteotech first entered into an agreement with CTS in March 2006 under which CTS agreed to supply a specific number of cortical bone tissues to Osteotech each month. In February the parties amended the agreement to more than double the number of cortical bone tissues to be supplied by CTS to Osteotech each month. In May, CTS agreed to supply Osteotech with an annual minimum number of whole donors. The initial five-year term of the agreement began in March 2006 and will automatically renew for successive two-year terms unless terminated by either party six months prior to renewal.

• Regeneration Technologies (RTI; Alachua, Florida), a processor of orthopedic and other biologic implants, and Zimmer Holdings (Warsaw, Indiana) have signed an exclusive 10-year distribution agreement for a new allograft paste implant. The bone paste implant — composed of inductive and carrier elements that are derived solely from human bone -- will be delivered in flowable and moldable formulations. The paste is comprised of allograft tissue that must pass a rigorous in vivo rat assay designed to screen out potentially underperforming and inflammatory demineralized bone from use. FInitial shipments of the paste to Zimmer are expected during 4Q07.

• Royal Philips Electronics (Amsterdam, The Netherlands) and healthcare IT provider Misys Healthcare Systems (Raleigh, North Carolina) will collaborate in developing an software platform that enables homecare agencies to provide care to chronically ill patients. The companies will combine Philips’ experience in telehealth and remote patient monitoring with Misys’ expertise in clinical and business software for U.S. homecare. They offer integration of vital signs data and health status information into the patient record, providing a comprehensive clinical review application than currently available. The goal is to provide a solution that helps homecare agencies reduce hospital readmissions and healthcare costs associated with chronic disease. Philips and Misys will also be co-marketing their existing products in the homecare market, Philips remote patient monitoring and Misys Homecare integrated clinical solution.

• Smith & Nephew Orthopaedic Trauma & Clinical Therapies (S&N; Memphis) has entered into an agreement with Teknimed (Toulouse, France) to sell Teknimed’s Spine Fix product in North America, Europe and Australia. The Spine Fix product, used to treat painful compression fractures in the spine, is a ready-to-use, self-hardening bone cement injected into the vertebrae through a minimally invasive procedure known as a vertebroplasty or kyphoplasty. Spine Fix is designed to be a low-risk procedure that offers patients reduction in pain and an improvement in mobility, the company said. The procedure can take less than one hour, and pain relief can be felt as quickly as 25 minutes following the procedure. The product has been launched in Europe, and S&N will roll out the product to the U.S. in 3Q07.

• Welch Allyn (Skaneateles Falls, New York) and Masimo (Irvine, California) reported a partnership to incorporate Masimo SET pulse oximetry into new versions of the Welch Allyn Spot Vital Signs and Welch Allyn Propaq LT devices. The two devices allow clinicians to spot check and monitor patients respectively in ambulatory and acute care settings, and they can be configured for efficient operation by caregivers with varying levels of training and sophistication, according to the companies.

No Comments